Immunomedics (IMMU) - moderated | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Immunomedics (IMMU) - moderated

An SI Board Since September 2006

Posts	SubjectMarks	Bans	Symbol
63361	356	15	IMMU

Emcee: idahoranch1	Type: Moderated

Introduction Market Data Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
63182	Added more SRPT a little while ago in the mid-10's. But I was afraid to buy	Olecranon	-	7/24/2025
63181	SRPT: talk about a divergence of analyst opinions this morning ........ Citigr	luckydog88	1	7/24/2025
63180	Interesting that Goldman Sachs just downgraded IOVA (to $1.00), we all remember	Stikkmann	1	7/23/2025
63179	Anyone following IOVA? Seems to be moving with good volume. Thoughts? TIA	CFL Invest 1	1	7/22/2025
63178	I wasn't crazy about Sarepta defying FDA brass, but I could see why they did	ghettogoulash	1	7/22/2025
63177	CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (SRPT) , the lead	luckydog88	-	7/21/2025
63176	Don't know much about RFK, but his recent comments do not seem threatening,	ghettogoulash	-	7/21/2025
63175	Elevedis is in ambulatory patients has quickly jumped over PMO as SRPT’s greates	Olecranon	-	7/21/2025
63174	certainly looks like RFK is out to get them, whether it is deserved in some case	luckydog88	1	7/21/2025
63173	This doesn't look like good news: investorrelations.sarepta.com Excerpts:	erickerickson	-	7/21/2025
63172	Sarepta issues letter to Duchenne community: share.google	ghettogoulash	3	7/19/2025
63171	Dr. Marty Makary, the F.D.A. commissioner, said in the agency’s statement that i	ghettogoulash	1	7/18/2025
63170	There was a plea today on STAT news from two activist mothers of Duchenne patien	ghettogoulash	2	7/18/2025
63169	CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (SRPT) , the lead	luckydog88	1	7/18/2025
63168	FDA was already aware of the patient death in the Phase 1 trial of SRP-9004. Sar	ghettogoulash	1	7/18/2025
63167	I juat assumed they knew it yesterday. Probably knew it for weeks or a month.	Olecranon	-	7/18/2025
63166	They knew this yesterday during conference call: Exclusive-US FDA to ask Sarept	TripleE3	-	7/18/2025
63165	BRIEF-Sarepta Says 51-Year-Old Male Patient Died In Early Stage Study Of SRP-900	luckydog88	-	7/18/2025
63164	agreed - sold the extra I bought this morning, guess I own enough already. just	luckydog88	-	7/18/2025
63163	This may be a case of don't try to catch a falling knife....	Davidoff	1	7/18/2025
63162	wow - $14 and change pre-market ....... fingers crossed ..... just bought some	luckydog88	-	7/18/2025
63161	SRPT 3rd Death from Liver Toxicity A month ago?! After yesterday's confere	TripleE3	-	7/17/2025
63160	and a third one came across the wires: Baird analyst Brian Skorney maintains Sa	luckydog88	1	7/17/2025
63159	this one not as positive: RBC Lowers Price Target on Sarepta Therapeutics to $2	luckydog88	-	7/17/2025
63158	Needham analyst Gil Blum reiterates Sarepta Therapeutics(SRPT) with a Buy and ma	luckydog88	1	7/17/2025

Go to reply# or date (mm/dd/yy):